UCSF Navigation Bar

UCSF Departments of Pathology & Laboratory Medicine Home Page

Lab Manual for UCSF Clinical Laboratories

Lab Manual for SFGH

Internal Resources

Shibani Pati, MD, PhD

Research and Clinical Interests

I am a vascular biologist with an interest in the role of endothelial dysfunction and vascular compromise in the pathogenesis of human disease. My specific areas of investigation involve the use of stem cells and novel resuscitative modalities that can mitigate endothelial dysfunction in traumatic injury.

Abnormalities in vascular permeability leading to inflammation, tissue edema, and end-organ dysfunction significantly contribute to the morbidity and mortality associated with a number of human disease processes. For example, although a number of factors contribute to the high mortality and morbidity associated with traumatic brain injury (TBI), the development of cerebral edema with brain swelling remains one of the most significant predictors of outcome. Similarly both hemorrhagic shock and septic shock are characterized by abnormal vascular permeability, which contributes to the development of shock-associated acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Despite the clear importance of abnormal vascular permeability in a number of human disease processes, there exists no therapeutic modality in current use to attenuate it. Our research is focused on finding ways to mitigate vascular endothelial permeability, end organ damage and the Endotheliopathy of Trauma or EOT. My lab is currently funded by the NIH, private industry and the Department of Defense (DOD). We are currently part of a multi-center DOD funded trial based out of UCSF to investigate the use of MSCs in trauma induced ARDS (PI Matthay-UCSF).

Conference on Cellular Therapies in Trauma and Critical Care Medicine

We have now organized and hosted three conferences that have been focused upon cellular therapies in trauma and critical care. All three have been sponsored by CIRM.The first was held in 2012 and the most recent meeting was held in May, 2017. The website for the meeting is www.cttacc.org. The goal of this meeting is to bring together the expertise and input of blood bankers, clinicians running trials, basic scientists, companies, FDA, NIH, AABB, and the DOD representatives to discuss existing barriers in the translation of cell therapies in trauma and critical care medicine, a field with few therapeutic options. The areas covered spanned translationally relevant topics such as cell sourcing, cell expansion, cell storage, safety, funding, pre-clinical studies and clinical trials. Our speakers had diverse expertise and knowledge in these areas. Our target audience included clinicians, physician- scientists, and basic scientists who are currently working in or anticipate working in the field of cellular therapeutics in critically ill patients. There will be a supplement in the journal Transfusion that highlights a number of the talks from CTTACC 2017. The next meeting is scheduled for May, 2019.

Selected Publications

  • Pati S, Rasmussen TE. Cellular therapies in trauma and critical care medicine: Looking towards the future. PLoS Med. 2017 Jul 11;14(7):e1002343. doi: 10.1371/journal.pmed.1002343. eCollection 2017 Jul. PMID: 28700606

  • Pati S, Pilia M, Grimsley JM, Karanikas AT, Oyeniyi B, Holcomb JB, Cap AP, Rasmussen TE. Cellular Therapies in Trauma and Critical Care Medicine: Forging New Frontiers SHOCK 2015 Dec;44(6):505-23

  • Gyulnar Baimukanova, Byron Miyazawa, Daniel Potter, Marcus Muench, Roberta Bruhn, Stuart L. Gibb, Philip C. Spinella, Andrew P. Cap, Mitchell Cohen, Shibani Pati. Platelets Regulate Vascular Endothelial Stability: Assessing the Storage Lesion and Donor Variability of Apheresis Platelets. Transfusion. 2016 Mar;56 Suppl1:S65-75. doi: 10.1111/trf.13532.

  • Gyulinar Baikumanova, Byron Miyazawa, Daniel Potter, Stuart Gibb, Sheila Keating, Ali Danesh1, Ashley Beyer, Yelena Dayter, Roberta Bruhn,, Marcus Muench1,, Andrew P. Cap, Philip J. Norris, Philip Spinella, Mitchell Cohen and Shibani Pati. The effects of 22°C and 4°C storage of platelets on vascular endothelial integrity and function Transfusion. 2016 Mar;56 Suppl 1:S52-64. doi: 10.1111/trf.13455.

  • Pati S, Potter DR, Baikamunova G, Farrell DH, Holcomb JB, Schreiber MA. Modulating the Endotheliopathy of Trauma: factor Concentrate vs. Fresh Frozen Plasma J Trauma Acute Care Surg. 2016 Jan 21.

  • Holcomb JB, Pati S. Optimal trauma resuscitation with plasma as the primary resuscitative fluid: the surgeon's perspective. Hematology Am Soc Hematol Educ Program. 2013;2013:656-9

  • Menge T, Zhao Y, Zhao J, Wataha, K, Gerber M, Zhang J, Letourneau P, Redell J, Shen L, Wang J, Peng Z, Xue H, Kozar R, Cox CS Jr, Khakoo AY, Holcomb JB, Dash PK, Pati S. Mesenchymal stem cells regulate blood-brain barrier integrity through TIMP3 release after traumatic brain injury. Sci Transl Med;4: 161ra50.

  • Pati S, Gerber MH, Menge TD, Wataha KA, Zhao Y, Baumgartner JA, Zhao J, Letourneau PA, Huby MP, Baer LA, Salsbury JR, Kozar RA, Wade CE, Walker PA, Dash PK, Cox CS Jr, Doursout MF, Holcomb JB. Bone marrow derived mesenchymal stem cells inhibit inflammation and preserve vascular endothelial integrity in the lungs after hemorrhagic shock. PLoS One. 2011;6(9):e25171. Epub 2011 Sep 28 PMID: 21980392

  • Pati S, Khakoo AY, Zhao J, Jimenez F, Gerber M, Harting MT, Redell JB, Grill RJ, Matsuo Y, Guha S, Cox CS, Reitz MS, Holcomb JB, Dash PK. Human mesenchymal stem cells inhibit vascular permeability by modulating VE-cadherin/beta-catenin signaling. Stem Cells Dev. 2010 May 6. [Epub ahead of print] PMID: 20446815

  • Pati S, Matijevic N, Doursout MF, Ko T, Cao Y, Deng X, Kozar RA, Hartwell E, Conyers J, Holcomb JB. Protective effects of fresh frozen plasma on vascular endothelial permeability, coagulation, and resuscitation after hemorrhagic shock are time dependent and diminish between days 0 and 5 after thaw. J of Trauma. 2010 Jul;69 Suppl 1:S55-63. PMID: 20622621

  • Pati S.*, Khakoo AY., Anderson SA., Reid W., Elshal MF., Rovira II, Nguyen AT., Malide D., Combs CA., Hall G., Zhang J., Raffeld M., Rogers TB., Stetler-Stevenson W., Franks JA., Reitz M., Finkel T. Human Mesenchymal Stem Cells exert potent antitumorigenic effects in a model of Kaposi's Sarcoma. J. Exp. Med. 2006 May 15;203(5):1235-47. *Indicates Co-first author

Selected Awards

  • 2009 Mission Connect Award (TIRR Foundation) for research in High throughput Screening of Drugs
  • 2009 Mission Connect (TIRR Foundation Award) for the study of the Immunomodulatory effects of MAPCs in TBI
  • 2006 Vivian L. Smith Postdoctoral Fellow Award in Neurocognitive Disorders
  • 2007 NIH LRP Award for Pediatric Research in TBI
  • 2009 NIH LRP Award for Pediatric Research in TBI
  • 2009 Mission Connect Award (TIRR Foundation) for research in High throughput Screening of Drugs for motor neuron stem cell differentiation and survival
  • 2011 Scott Murphy Guest Lectureship BEST/AABB San Diego
  • 2014 Blood Systems Inc. TOP Performer $10,000 Award
  • 2015 Shelton Foundation Neuro-military Award for Research in TBI
Shibani Pati, MD, PhD
  • Associate Professor in Residence -UCSF Department of Laboratory Medicine
  • Scientific Director of Cellular Therapies Department of Lab Medicine at UCSF
  • Laboratory Medicine

Specialty Areas

  • Stem cell therapeutics and stem cell derived factors in trauma and critical care medicine
  • Control of vascular leak in disease and mitigating endothelial damage
  • Novel Resuscitative Modalities- plasma (FFP), platelets, Lyophilized plasma, pathogen reduced plasma, factor concentrate
  • Storage Lesion of FFP and Platelets
  • Trauma induced ARDS, Stem cell therapies in traumatic brain injury (TBI) and spinal cord injury (SCI)

Contact Information

Mailing/Shipping Address:

  • UCSF
  • Shibani Pati, MD, PhD
  • Laboratory Medicine, Box 0100
  • 513 Parnassus Avenue, HSE-715
  • San Francisco, CA 94143

Web Site

Other UCSF Organizational Association(s)

  • Blood Systems Research Institute
UCSF home page UCSF home page About UCSF Search UCSF UCSF Medical Center